Sarcosine for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

Sarcosine for Health & Longevity

Created on 08/14/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

A cheap, naturally occurring amino acid that raises activity at one of the brain's main excitatory receptors and falls with age. Trials show reduced withdrawal and flattening in long-standing psychosis, an effect absent alongside one antipsychotic. Longevity evidence is entirely cells and animals. A prostate cancer signal remains unresolved, and nothing beyond six months has been observed. (Full Review)

Protocol

Standard dose
2 g daily
Dose used in almost every controlled trial; Examine expresses the same target as roughly 30 mg per kilogram of body weight.
Time of day
Morning
Standard in the trials. The excitatory mechanism argues against evening administration; no trial has compared timing directly.
Split versus single dose
Once daily
All published trials used once-daily dosing. The half-life near one hour argues for splitting 2 g into two 1 g doses, but that schedule is inference, not tested practice.
Time to effect
Symptom change
Week 2
Week 1 in one open-label study, week 2 in most randomized trials, on the overall and negative symptom burden of schizophrenia.
Obsessive-compulsive symptoms
Week 4
Onset within four weeks in a ten-week open-label trial. Stopping before week 4 is a documented pitfall.
Cognition
12 weeks
Trials measuring cognition ran 12 weeks before separation appeared.

Benefits

Contraindications
  • Men with active, untreated, or biochemically recurrent prostate cancer, or a confirmed prostate-specific antigen rise above 4.0 ng/mL pending workup
  • People taking clozapine
  • Pregnancy and lactation
  • Severe renal impairment (eGFR below 30 mL/min/1.73 m²)
  • Active seizure disorder or stroke within 90 days
  • Children and adolescents outside a supervised trial setting
    •
Key Interactions
  • NMDA receptor antagonists (memantine, ketamine, esketamine)
  • Other antipsychotics (risperidone, olanzapine, first-generation agents)
  • Sodium benzoate
  • Glycine and D-serine supplements
  • Over-the-counter dextromethorphan
  • Over-the-counter magnesium
  • Prolonged fasting and calorie restriction
    •

Risk & Side Effects

  • High: Mild, transient adverse effects
    •
  • Medium: Promotion of prostate cancer invasion (conflicted)
    •
  • Low: Excitatory overstimulation; interference with laboratory assays
  • Speculative: Perturbation of one-carbon and methyl-group balance
    •

Monitoring

Marker Target Why
PSA, total Below 1.0 ng/mL under age 60; below 1.5 ng/mL from 60 Tracks the prostate signal that the cancer-biology data raise
Free PSA, percentage of total Above 25% Separates benign enlargement from cancer when total PSA rises
eGFR Above 90 mL/min/1.73 m² Sarcosine and the glycine it yields are cleared by the kidney
ALT Below 25 U/L in men, below 20 U/L in women The enzyme producing sarcosine is liver-based; disturbance shows here first
Homocysteine Below 9 µmol/L Reads the one-carbon pathway that sarcosine breakdown feeds
Serum sarcosine or glycine No established target exists; track the change from the individual's own baseline instead Confirms that oral dosing actually moves the metabolite

Cadence: Baseline panel before the first dose, repeated at 3 months, again at 6 months, and thereafter every 6–12 months for as long as use continues, with prostate markers on the same schedule.

Qualitative Assessment

  • Sleep onset latency and any new difficulty falling asleep
  • Mental clarity and speed of processing during demanding tasks
  • Mood stability and motivation, using a consistent self-rating
  • Verbal fluency and social engagement, the domains where negative-symptom benefit appears
  • Headache, nausea, and any sense of overstimulation in the first three weeks
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.